Human IFN-α Antibody - Rontalizumab Biosimilar
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Anti-hIFNα-IgG Human IFN-α (Rontalizumab) antibody - Human IgG1 |
Show product |
200 µg |
hifna-mab1-02
|
|
Anti-human IFN alpha - Rontalizumab biosimilar - CAS #948570-30-7
Binding of Anti-hIFN-α Rontalizumab
InvivoGen also offers:
• Recombinant human IFN-α2b
• Other IFN-α subtypes upon request
• IFN-α/β reporter HEK 293 cells
• Anti-hIFNAR (Anifrolumab)
Anti-hIFN-α-hIgG1 is a biosimilar antibody of Rontalizumab, a therapeutic antibody that targets interferon alpha (IFN-α). This monoclonal antibody (mAb) blocks the interaction of IFN-α with its receptor. Rontalizumab has been clinically evaluated as an immunosuppressive agent for the treatment of systemic lupus erythematosus (SLE).
Anti-hIFN-α-hIgG1 comprises the variable region of Rontalizumab and the human IgG1 constant region of Rontalizumab with high effector functions.
This antibody can be used with HEK-Blue™ IFN-α/β cells for screening and neutralization assays to block recombinant human IFN-α-induced signaling (see figure).
Key features
- Potent and specific neutralization activity against hIFN-α2
- Reacts with hIFN-α1, hIFN-α2, hIFN-α5, hIFN-α8, hIFN-α14, hIFN-α16, hIFN-α17, and hIFN-α21
- Weakly reacts with hIFN-α4 and IFN-α10
- Does not react with hIFN-α6 or hIFN-α7
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct was verified.
- The absence of endotoxins is determined using the EndotoxDetect™ assay.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
Back to the topSpecifications
Application: Neutralization assay, ELISA
Isotype: Human IgG1, kappa
Recommended isotype control: Human IgG1
Target: Human IFN-α2. Note: This mAb also reacts with human IFN-α1, IFN-α5, IFN-α8, IFN-α14, IFN-α16, IFN-α17, and IFN-α21. It very weakly reacts with human IFN-α4 and IFN-α10. It does not react with IFN-α6 or IFN-α7 (In-house data).
Species reactivity: Human
Clone: Rontalizumab
Cas number: 948570-30-7
Source: CHO cells
Production: Animal-free
Purification: Protein A
Molecular weight: ~ 150 kDa
Physical form: Lyophilized
Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Preservative: Azide-free
Reconstitution buffer: Sterile water (not provided)
Purity: ≥ 95 %
Quality control: Each lot is functionally tested and validated.
Back to the topContents
- 200 µg of purified Anti-hIFN-α-IgG antibody, provided azide-free and lyophilized.
The product is shipped at room temperature.
Store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year.
Avoid repeated freeze-thaw cycles.
Details
Rontalizumab background
Rontalizumab (aka rhuMAb interferon-alpha) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human interferon-alpha (IFN-α) cytokine subtypes [1, 2]. By binding to IFN-α, Rontalizumab prevents it from interacting with its receptor (IFNAR) on the surface of immune cells, thus inhibiting the downstream inflammatory response. Rontalizumab has been clinically evaluated as an immunosuppressive agent for the treatment of systemic lupus erythematosus (SLE) [1-3].
References:
1. McBride JM, et al. 2012. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 64(11):3666-76.
2. Kalunian KC, et al., 2016. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. (2016) 75:196–202.
3. Jones, S.A. and Morand, E.F., 2024. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned. Drugs. 84(6):625-635.